Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter of Fiscal Year 2011 (Q1 FY11), ended June 30, 2010.
Business Overview: An emerging global pharmaceutical company operating through three core businesses: Pharmaceutical Services & Active Ingredients (PSAI), Global Generics, and Proprietary Products.
Key Financial Metrics
| Metric | Q1 FY11 (INR) | Q1 FY11 (USD) | Q1 FY10 (INR) | Q1 FY10 (USD) |
|---|---|---|---|---|
| Revenue | 16,831 million | 363 million | 18,189 million | 392 million |
| Gross Profit | 8,914 million | 192 million | 10,172 million | 219 million |
| Gross Margin | 53% | - | 56% | - |
| EBITDA | 3,400 million | 74 million | - | - |
| EBITDA Margin | 20% | - | - | - |
| Profit Before Tax | 2,453 million | 53 million | 3,171 million | 68 million |
| Profit After Tax | 2,096 million | 45 million | 2,445 million | 53 million |
| Diluted EPS | 12.3 | 0.3 | 14.4 | 0.3 |
Liquidity and Balance Sheet (as of June 30, 2010):
- Cash and cash equivalents: Rs. 6,366 million ($137 million)
- Loans and borrowings: Rs. 13,872 million ($299 million)
- Capital expenditure for the quarter: Rs. 1,900 million ($40 million)
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenue decreased by 7% year-over-year (YoY) to Rs. 16.8 billion. Excluding sumatriptan revenues from the prior year, organic growth was 4%.
- Profitability Pressure: Profit after tax declined 14% YoY to Rs. 2.1 billion. Gross margin contracted from 56% to 53%, primarily due to the absence of high-margin sumatriptan sales in the current quarter.
- Segment Performance:
- Global Generics: Revenue fell 8% YoY to Rs. 11.9 billion. Excluding sumatriptan, growth was 9%. North America revenue dropped 35% (excluding sumatriptan, down 5% in USD terms), while Russia & CIS grew 36%.
- PSAI: Revenue declined 8% YoY to Rs. 4.5 billion.
- Expense Management: SG&A expenses (excluding amortization) declined 4% YoY. However, excluding one-time restructuring charges from the prior year, SG&A grew 7%. Amortization expenses dropped significantly to Rs. 288 million from Rs. 507 million due to prior impairment.
- Foreign Exchange: Net forex loss increased to Rs. 225 million ($5 million) from Rs. 84 million ($2 million) in the prior year.
Outlook, Commentary, and Risks
- Strategic Transactions: The company transferred dossiers and trademarks for nine marketed products in Brazil to GSK for $4 million, with potential milestone payments for pipeline products.
- Product Pipeline: Launched 32 new generic products, filed 26 new product registrations, and 3 DMFs globally during the quarter. Cumulative ANDA filings stand at 163, with 71 pending USFDA approval.
- Market Growth: Secondary prescription sales growth in Russia (33%) and India (22%) outpaced industry averages.
- Corporate Actions: The 26th Annual General Meeting approved a dividend of Rs. 11.25 per share (225%) and the re-appointment of directors.
- Risks: Forward-looking statements are subject to risks including global economic conditions, market acceptance of products, technological changes, and exposure to market risks.
Investor Verification Checklist
- Sumatriptan Impact: Verify the extent to which the revenue and margin decline is attributable to the loss of sumatriptan sales versus underlying operational performance.
- North America Exposure: Assess the sustainability of the 35% revenue drop in North America and the pipeline status of the 71 pending ANDAs.
- Foreign Exchange Sensitivity: Monitor the impact of currency fluctuations, given the significant increase in forex losses this quarter.
- One-Time Charges: Confirm the normalization of SG&A expenses by excluding the prior year's one-time restructuring costs (Betapharm and Atlanta facility closure).
- Brazil Deal Milestones: Track the progress of the GSK agreement to determine potential future revenue recognition from milestone payments.